The use of amniotic membrane for reconstructive heart surgery
Research type
Research Study
Full title
Developing a novel Advanced Tissue Engineered Product for correction of paediatric Tetralogy of Fallot/Pulmonary Atresia
IRAS ID
323571
Contact name
Massimo Caputo
Contact email
Sponsor organisation
University of Bristol, Research & Enterprise Division
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Congenital heart defect (CHD) affects 9 per 1,000 live births in the UK. Despite being lifesaving, currently used replacement grafts suffer many limitations, as they do not grow with the babies and tend to fail after few months or years, requiring multiple open-heart surgical operation throughout children’s life. We are proposing to generate a novel Advanced Tissue Engineered Prosthesis for correction of complex CHD, whereby the amniotic membrane and the umbilical cord- derived mesenchymal stromal cells will be the crucial components of the prosthesis. Our proposed ATEP promises to remarkably impact on the need of additional surgical interventions, as our encouraging preliminary data show. Through this study, we will collect the placenta and umbilical cord from normal pregnancy to obtain the amniotic membrane and the cells components needed for the manufacturing of the ATEP.
REC name
Wales REC 5
REC reference
23/WA/0119
Date of REC Opinion
7 Jun 2023
REC opinion
Further Information Favourable Opinion